结核分枝杆菌乙胺丁醇耐药机制的研究进展

doi:10.16288/j.yczz.16-111

[an error occurred while processing this directive]

Hereditas(Beijing) ›› 2016, Vol. 38 ›› Issue (10): 910-917.doi: 10.16288/j.yczz.16-111

• Reviews • Previous Articles Next Articles

Progress on mechanism of ethambutol resistance in Mycobacterium Tuberculosis

Ting Wang, Weiwei Jiao, Adong Shen

Key Laboratory of Major Diseases in Children and National Key Discipline of Pediatrics (Capital Medical University), Ministry of Education, Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China

Received:2016-04-01 Revised:2016-07-28 Online:2016-10-20 Published:2016-10-20
Supported by:
[Supported by the National Natural Science Foundation of China (Nos; 81271889,30901632)]

Abstract

Abstract: The occurance and prevalence of multidrug-resistant tuberculosis poses a serious threat to the global tuberculosis control. Ethambutol (EMB) is one of the first-line anti-tuberculosis drugs, which is usually used in combination with isoniazid and rifampicin for treating pan-sensitive tuberculosis, and it can also be used in drug-resistant tuberculosis. However, the situation of EMB resistance is alarmingly high, especially in multi-drug resistant tuberculosis. In China, EMB resistance rate in the previously treated cases was up to 17.2% and showed an increased tendency. What was worse, 51.3%-66.7% of multidrug-resistant tuberculosis cases were resistant to EMB. Thus, it is important to understand the drug resistance mechanism of EMB, which will help to slow down the drug resistance rate of EMB. In this review, we focus on the current status of EMB resistance, the effects of EMB and the mechanisms of EMB resistance in Mycobacterium tuberculosis.

Key words: Mycobacterium tuberculosis, ethambutol, drug resistance

Ting Wang, Weiwei Jiao, Adong Shen. Progress on mechanism of ethambutol resistance in Mycobacterium Tuberculosis[J]. Hereditas(Beijing), 2016, 38(10): 910-917.

References

[1] World Health Organization. Global tuberculosis report 2015. Geneva: World Health Organization, 2015.
[2] He GX, Zhao YL, Jiang GL, Liu YH, Xia H, Wang SF, Wang LX, Borgdorff MW, van der Werf MJ, van den Hof S. Prevalence of tuberculosis drug resistance in 10 provinces of China. BMC Infect Dis , 2008, 8(1): 166.
[3] Zhao YL, Xu SF, Wang LX, Chin DP, Wang SF, Jiang GL, Xia H, Zhou Y, Li Q, Ou XC, Pang Y, Song YY, Zhao B, Zhang HT, He GX, Guo J, Wang Y. National survey of drug-resistant tuberculosis in China. N Engl J Med , 2012, 366(23): 2161-2170.
[4] Gonzalo X, Hutchison DC, Drobniewski FA, Pimkina E, Davidaviciene E. Multidrug-resistant tuberculosis in the United Kingdom and Lithuania. Int J Tuberc Lung Dis , 2014, 18(6): 663-665.
[5] Zhang ZJ, Wang YG, Pang Y, Kam KM. Ethambutol resistance as determined by broth dilution method correlates better than sequencing results with embB mutations in multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol , 2014, 52(2): 638-641.
[6] Chen QY, Pang Y, Liang QF, Lin SF, Wang YF, Lin J, Zhao Y, Wei SZ, Zheng JF, Zheng SH. Molecular characteristics of MDR Mycobacterium tuberculosis strains isolated in Fujian, China. Tuberculosis , 2014, 94(2): 159-161.
[7] Shi DW, Li L, Zhao YL, Jia Q, Li H, Coulter C, Jin Q, Zhu GF. Characteristics of embB mutations in multidrug- resistant Mycobacterium tuberculosis isolates in Henan, China. J Antimicrob Chemother , 2011, 66(10): 2240-2247.
[8] Chatterjee D. The mycobacterial cell wall: structure, biosynthesis and sites of drug action. Curr Opin Chem Biol , 1997, 1(4): 579-588.
[9] Jankute M, Grover S, Rana AK, Besra GS. Arabinogalactan and lipoarabinomannan biosynthesis: structure, biogenesis and their potential as drug targets. Future Microbiol , 2012, 7(1): 129-147.
[10] Srivastava S, Ayyagari A, Dhole TN, Nyati KK, Dwivedi SK. emb nucleotide polymorphisms and the role of embB 306 mutations in Mycobacterium tuberculosis resistance to ethambutol. Int J Med Microbiol , 2009, 299(4): 269-280.
[11] Ramaswamy SV, Amin AG, Göksel S, Stager CE, Dou SJ, El Sahly H, Moghazeh SL, Kreiswirth BN, Musser JM. Molecular genetic analysis of nucleotide polymorphisms associated with ethambutol resistance in human isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother , 2000, 44(2): 326-336.
[12] Ahmad S, Jaber AA, Mokaddas E. Frequency of embB codon 306 mutations in ethambutol-susceptible and-resistant clinical Mycobacterium tuberculosis isolates in Kuwait. Tuberculosis , 2007, 87(2): 123-129.
[13] Mokrousov I, Otten T, Vyshnevskiy B, Narvskaya O. Detection of embB306 mutations in ethambutol-susceptible clinical isolates of Mycobacterium tuberculosis from northwestern Russia: implications for genotypic resistance testing. J Clin Microbiol , 2002, 40(10): 3810-3813.
[14] Hazbón MH, Bobadilla del Valle M, Guerrero MI, Varma-Basil M, Filliol I, Cavatore M, Colangeli R, Safi H, Billman-Jacobe H, Lavender C, Fyfe J, García-García L, Davidow A, Brimacombe M, León CI, Porras T, Bose M, Chaves F, Eisenach KD, Sifuentes-Osornio J, Ponce de León A, Cave MD, Alland D. Role of embB codon 306 mutations in Mycobacterium tuberculosis revisited: a novel association with broad drug resistance and IS 6110 clustering rather than ethambutol resistance. Antimicrob Agents Chemother , 2005, 49(9): 3794-3802.
[15] Madison B, Robinson-Dunn B, George I, Gross W, Lipman H, Metchock B, Sloutsky A, Washabaugh G, Mazurek G, Ridderhof J. Multicenter evaluation of ethambutol susceptibility testing of Mycobacterium tuberculosis by agar proportion and radiometric methods. J Clin Microbiol , 2002, 40(11): 3976-3979.
[16] Safi H, Sayers B, Hazbón MH, Alland D. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin. Antimicrob Agents Chemother , 2008, 52(6): 2027-203

Metrics

Comments

www.chinagene.cn
备案号：京ICP备09063187号

Progress on mechanism of ethambutol resistance in Mycobacterium Tuberculosis

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 10

Recommended Articles

Metrics

Comments

[1]	Huxing Chen, Lei Xu, Jing Li, Zheng Guo, Lu Ao. The development of a general drug resistance score model based on MIC₅₀ related gene pairs in colorectal cancer cell lines [J]. Hereditas(Beijing), 2020, 42(6): 577-585.
[2]	Liyuan Zhang, Fujing Huang, Junqi Xu, Zhen Gong, Jianping Xie. Acid-resistant genes in Mycobacterium tuberculosis and the underlying regulatory network [J]. Hereditas(Beijing), 2018, 40(7): 546-560.
[3]	Wei Gao, Wei Shi, Changhui Chen, Denian Wen, Jin Tian, Kaihu Yao. Epidemiological study on the penicillin resistance of clinical Streptococcus pneumoniae isolates identified as the common sequence types [J]. Hereditas(Beijing), 2016, 38(10): 940-947.
[4]	Yang Liu, Bangxing Wang, Zhiyong Liu, Yi Han, Yaoju Tan, Xinjie Li, Jianxiong Liu, Shouyong Tan, Tianyu Zhang. Progress in resistance mechanisms and diagnosis of non-first line anti-TB drugs [J]. Hereditas(Beijing), 2016, 38(10): 928-939.
[5]	Yujiao Zhang, Xiaojing Li, Kaixia Mi. Mechanisms of fluoroquinolone resistance in Mycobacterium tuberculosis [J]. Hereditas(Beijing), 2016, 38(10): 918-927.
[6]	Yufan Chen, Shiyin Liu, Zhibin Liang, Mingfa Lv, Jianuan Zhou, Lianhui Zhang. Quorum sensing and microbial drug resistance [J]. Hereditas(Beijing), 2016, 38(10): 881-893.
[7]	Yancheng Yang, Hang Cheng, Renjie Zhou, Xiancai Rao. Application of the SCCmec element in the molecular typing of methicillin-resistant Staphylococcus aureus [J]. HEREDITAS(Beijing), 2015, 37(5): 442-451.
[8]	Xinxin Si, Yujie Sun. Aberrant DNA methylation and drug resistance of tumor cells [J]. HEREDITAS(Beijing), 2014, 36(5): 411-419.
[9]	WU Xin-Gang PENG Shu-Bin HUANG Qian. Transcriptional regulation of breast cancer resistance protein [J]. HEREDITAS, 2012, 34(12): 1529-1536.
[10]	WANG Qian, CUI Zhi-Feng. Pleiotropic drug resistance ABC transporters in fungi [J]. HEREDITAS, 2011, 33(10): 1048-1056.